Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies
@article{Ratti2013FullCN, title={Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies}, author={E. Ratti and P. Bettica and Robert Alexander and G. Archer and D. Carpenter and G. Evoniuk and R. Gomeni and Erica L. Lawson and M. L{\'o}pez and H. Millns and E. Rabiner and D. Trist and Michael Trower and S. Zamuner and R. Krishnan and M. Fava}, journal={Journal of Psychopharmacology}, year={2013}, volume={27}, pages={424 - 434} }
Full, persistent blockade of central neurokinin-1 (NK1) receptors may be a potential antidepressant mechanism. The selective NK1 antagonist orvepitant (GW823296) was used to test this hypothesis. A preliminary positron emission tomography study in eight male volunteers drove dose selection for two randomized six week studies in patients with major depressive disorder (MDD). Displacement of central [11C]GR205171 binding indicated that oral orvepitant doses of 30–60 mg/day provided >99% receptor… CONTINUE READING
Supplemental Clinical Trials
Interventional Clinical Trial
This is a 6-week, randomised, multicenter, double-blind, placebo controlled, fixed dose
parallel group study to assess the efficacy and safety of orvepitant (30 and 60 mg/day… Expand
Conditions | Depressive Disorder |
---|---|
Intervention | Drug, Other |
Interventional Clinical Trial
This is a 6-week, randomised, multicenter, double-blind, placebo controlled, fixed dose
parallel group study to assess the efficacy and safety of orvepitant (30 and 60 mg/day… Expand
Conditions | Depressive Disorder, Major |
---|---|
Intervention | Drug, Other |
Paper Mentions
Interventional Clinical Trial
This is a 12-week, randomized, multicenter, double-blind, placebo controlled, fixed-dose
parallel group study to assess the efficacy and safety of orvepitant (60 mg/day) versus… Expand
Conditions | Post-Traumatic Stress Disorder |
---|---|
Intervention | Drug, Other |
42 Citations
Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder.
- Medicine
- The Journal of clinical psychiatry
- 2020
- 1
- PDF
Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial
- Medicine
- Menopause
- 2020
- 3
Why receptor reserve matters for neurokinin1 (NK1) receptor antagonists
- Medicine, Biology
- Journal of receptor and signal transduction research
- 2013
- 13
Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial
- Medicine
- BMJ Open
- 2020
- 3
- PDF
NK1 receptor antagonists for depression: Why a validated concept was abandoned.
- Medicine
- Journal of affective disorders
- 2017
- 17
Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia.
- Psychology, Medicine
- Sleep
- 2013
- 14
- PDF
Substance P and the Neurokinin-1 Receptor: The New CRF.
- Psychology, Medicine
- International review of neurobiology
- 2017
- 22
A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients
- Medicine
- Molecular Psychiatry
- 2016
- 15
- PDF
Neurokinin-1 Receptor Antagonists: Promising Agents in the Treatment of Chronic Pruritus
- Medicine
- Current Dermatology Reports
- 2017
Neurokinin‐1 receptor antagonist orvepitant is an effective inhibitor of itch‐associated response in a Mongolian gerbil model of scratching behaviour
- Biology, Medicine
- Experimental dermatology
- 2014
- 6
References
SHOWING 1-10 OF 43 REFERENCES
Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression
- Psychology, Medicine
- Neuropsychopharmacology
- 2004
- 236
- Highly Influential
- PDF
Lack of Efficacy of the Substance P (Neurokinin1 Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder
- Psychology, Medicine
- Biological Psychiatry
- 2006
- 265
Results From 2 Randomized, Double-Blind, Placebo-Controlled Studies of the Novel NK1 Receptor Antagonist Casopitant in Patients With Major Depressive Disorder
- Medicine
- Journal of clinical psychopharmacology
- 2011
- 58
Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
- Psychology, Medicine
- The Journal of clinical psychiatry
- 2009
- 126
- Highly Influential
A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder.
- Medicine, Psychology
- The Journal of clinical psychiatry
- 2011
- 103
- Highly Influential
Imaging substance P receptors (NK1) in the living human brain using positron emission tomography.
- Medicine
- The Journal of clinical psychiatry
- 2002
- 151
Do substance P and the NK1 receptor have a role in depression and anxiety?
- Medicine
- Current pharmaceutical design
- 2005
- 75
Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function.
- Medicine
- Proceedings of the National Academy of Sciences of the United States of America
- 2001
- 284
- PDF
Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: Comparison with antidepressant drugs
- Medicine
- Peptides
- 2005
- 70
Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
- Medicine
- The Journal of clinical psychiatry
- 2011
- 170
- Highly Influential